John Moriarty - Alexion Pharmaceuticals Senior Vice President General Counsel
President
Mr. John B. Moriarty, J.D., is Executive Vice President and General Counsel of the company. He was with Alexion since December 2012 and has served as Executive Vice President and General Counsel since September 2014. From December 2012 to September 2014, Mr. Moriarty served as Senior Vice President and General Counsel. From December 2010 to December 2012, Mr. Moriarty served as General Counsel and Chief Legal Officer at Elan Corporation plc, an Irish public limited company traded on the New York and Irish Stock Exchanges, and also served as a member of Elans Executive Management team. Prior to assuming the role of General Counsel, Mr. Moriarty served as Senior Vice President of Law, Litigation and Commercial Operations at Elan from December 2008 to December 2010. From 2002 to 2008, Mr. Moriarty held various positions with Amgen, Inc., including Executive Director and Associate General Counsel, Global Commercial Operations Amgen Oncology and Senior Counsel, Complex Litigation, Products Liability and Government Investigations. Between 1994 and 2002, Mr. Moriarty served in various capacities in private practice focused on healthcare and as a healthcare fraud prosecutor in the U.S. Attorneys Office and the Virginia Attorney Generals Office since 2014.
| Age | 49 |
| Tenure | 10 years |
| Phone | 475 230-2596 |
| Web | www.alexion.com |
Alexion Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of 10.08 % which means that it generated a profit of $10.08 on every $100 spent on assets. This is normal as compared to the sector avarege. Similarly, it shows a return on stockholder's equity (ROE) of 4.43 %, meaning that it created $4.43 on every $100 dollars invested by stockholders. Alexion Pharmaceuticals' management efficiency ratios could be used to measure how well Alexion Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.The company currently holds 2.88 B in liabilities with Debt to Equity (D/E) ratio of 0.23, which may suggest the company is not taking enough advantage from borrowing. Alexion Pharmaceuticals has a current ratio of 4.43, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Alexion Pharmaceuticals until it has trouble settling it off, either with new capital or with free cash flow. So, Alexion Pharmaceuticals' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Alexion Pharmaceuticals sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Alexion to invest in growth at high rates of return. When we think about Alexion Pharmaceuticals' use of debt, we should always consider it together with cash and equity.
Similar Executives
| Found 7 records | PRESIDENT Age | ||
| Brent Jewell | Apogee Enterprises | 49 | |
| Jamie Beggs | Avient Corp | 47 | |
| Jane Boyce | Apogee Enterprises | N/A | |
| David Davis | Sun Country Airlines | 57 | |
| Troy Johnson | Apogee Enterprises | 50 | |
| Sami Foguel | Azul SA | N/A | |
| Vinod Purayath | Avient Corp | 45 | |
Management Performance
| Return On Equity | 4.43 | |||
| Return On Asset | 10.08 |
Alexion Pharmaceuticals Leadership Team
Elected by the shareholders, the Alexion Pharmaceuticals' board of directors comprises two types of representatives: Alexion Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Alexion. The board's role is to monitor Alexion Pharmaceuticals' management team and ensure that shareholders' interests are well served. Alexion Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Alexion Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Edward Miller, Senior Vice President Global Chief Compliance Officer | ||
| David Anderson, CFO | ||
| Felix Baker, Director | ||
| Dominique Monnet, Senior Vice President Chief Marketing Officer | ||
| Saqib Islam, Senior Vice President Chief Strategy and Portfolio Officer | ||
| John Orloff, Executive Vice President Head of Research and Development | ||
| Ludwig Hantson, CEO, Director | ||
| Vikas Sinha, CFO, Executive Vice President | ||
| Andreas Rummelt, Independent Director | ||
| Julie ONeill, Executive Vice President - Global Operations | ||
| Brian Goff, Chief Commercial Officer | ||
| Clare Carmichael, Chief Human Resource Officer, Senior Vice President | ||
| Deborah Dunsire, Independent Director | ||
| Ellen Chiniara, Executive Vice President General Counsel, Corporate Secretary | ||
| Leonard Bell, CEO, Treasurer, Director | ||
| Paul Friedman, Director | ||
| Christopher Coughlin, Independent Director | ||
| Martin Mackay, Global Head of RandD and Executive VP | ||
| Heidi Wagner, Senior Vice President - Global Governmental Affairs | ||
| Ann Veneman, Independent Director | ||
| Paul Clancy, CFO | ||
| AnneMarie Law, Chief Patient and Employee Experience Officer, Executive Vice President | ||
| Francois Nader, Director | ||
| Judith Reinsdorf, Director | ||
| Indrani Franchini, Executive Vice President Chief Compliance Officer | ||
| John Moriarty, Senior Vice President General Counsel | ||
| Alvin Parven, Independent Director | ||
| Michele Burns, Independent Director | ||
| David Hallal, CEO and Director | ||
| Douglas Norby, Lead Independent Director | ||
| David Brennan, Independent Director | ||
| Carsten Thiel, Senior Vice President EMEA and Asia Pacific | ||
| John Mollen, Director |
Alexion Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Alexion Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 4.43 | |||
| Return On Asset | 10.08 | |||
| Profit Margin | 10.89 % | |||
| Operating Margin | 52.12 % | |||
| Current Valuation | 39.17 B | |||
| Shares Outstanding | 221.02 M | |||
| Shares Owned By Insiders | 0.34 % | |||
| Shares Owned By Institutions | 88.27 % | |||
| Number Of Shares Shorted | 8.46 M | |||
| Price To Earning | 58.24 X |
Pair Trading with Alexion Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Alexion Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Alexion Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to Apartment Investment could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Apartment Investment when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Apartment Investment - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Apartment Investment and to buy it.
The correlation of Apartment Investment is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Apartment Investment moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Apartment Investment and moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Apartment Investment can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in interest. You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Other Consideration for investing in Alexion Stock
If you are still planning to invest in Alexion Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Alexion Pharmaceuticals' history and understand the potential risks before investing.
| Stocks Directory Find actively traded stocks across global markets | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Money Managers Screen money managers from public funds and ETFs managed around the world |